Document:

Exhibit 10.1

    DANZIG,
      LTD.

    

    PRIVILEGED
      AND CONFIDENTIAL

    

    LETTER
      OF
      INTENT

    

    May
      1,
      2006

    

    Richard
      Pierce

    c/o
      Suite
      11405 - 201A Street

    Maple
      Ridge, British Columbia

    

    GFR
      Pharmaceuticals, Inc.

    c/o
      Suite
      11405 - 201A Street

    Maple
      Ridge, British Columbia

    

    

    Re: Sale
      of Shares in GFR Pharmaceuticals Inc. (“GFRP”)

    

    Dear
      Richard Pierce,

    

    I
      understand that you and/(or your associates) are the principal shareholder(s)
      of
      GFR Pharmaceuticals Inc. (“GFRP” or the “Company”) a Nevada corporation, which
      is a public corporation that has approximately 18 registered shareholders,
      and
      is looking for combination with an operating business. You have offered to
      sell
      200,000 shares out of the total of 570,000 shares in the Company which you
      own
      or control for the cash sum of $350,000, as part of the transactions outlined
      herein. There are currently a total of 1,079,940 shares
      outstanding.

    

    By
      this
      Letter of Intent, Danzig, Ltd. (“Danzig”) is accepting your offer, subject to
      the terms and conditions set out below:

    

    	1.  	
            At
              the closing the Board of Directors of GFRP will appoint Danzig’s nominees
              to the Board of Directors as additional directors of
              GFRP.

          

    

    	2.  	
            The
              Board of Directors will approve after appropriate review (with Pierce
              abstaining) the settlement of debt with GFR Pharma Ltd. and will approve
              the acceptance of shares of the capital stock of GFR Pharma Ltd., as
              full
              payment of said GFR Pharma Ltd. debt.

          

    

    	3.  	
            The
              Board of Directors will approve after appropriates review (with Pierce
              abstaining) the sale of all the shares in the capital of both GFR Pharma
              Ltd. and GFR Health Ltd. to Richard Pierce or his nominee, for $1.00
              in
              hand, and the release of all claims by Richard Pierce for reimbursement
              and/or indemnity for funds earned or advanced to the Company’s
              subsidiaries by Richard Pierce, and for lines of credit for the Company’s
              subsidiaries which have been guaranteed by
              Pierce.

          

    

    	4.  	
            Danzig
              and The 124 Group, Inc. and/or their designees, will purchase 200,000
              shares from Richard Pierce for the purchase price of US$350,000 at
              the
              closing .

          

    

    	5.  	
            The
              Board of Directors will also unanimously approve the issuance of 1,260,500
              restricted common shares to Danzig and 1,260,500 common shares to The
              124
              Group, Inc., and/or their designees for consulting services fully
              rendered, at the closing.

          

    

    	6.  	
            At
              the closing Danzig will cause to be delivered a cashier’s check for
              $350,000, or such other form of payment as accepted by Richard Pierce,
              concurrent with Pierce’s endorsement of 200,000 shares of currently
              outstanding common stock over to the
              Buyers.

          

    

    	7.  	
            Upon
              completion of the closing of the transactions, the current directors
              and
              the Company’s management will resign as directors and officers of the
              Company after nominating individuals selected by Danzig or its designee,
              to fill the vacancies thereby created.

          

    

    	8.  	
            The
              Board of Directors will thereafter promptly prepare and file the necessary
              United States Securities and Exchange Commission filings, including
              any
              required Form 8-K.

          

    

    	9.  	
            Immediately
              upon signing this LOI, Danzig and Danzig’s Buyer will have 30 days for
              completion of due diligence.

          

    

    	10.  	
            Upon
              signing this LOI and the completion of Danzig’s and its Buyer’s due
              diligence, Danzig will cause to be delivered a US$25,000 refundable
              deposit for the purchase price of the shares, which will be deposited
              with
              Davis & Associates in its attorney’s trust account, to be held as a
              deposit, and to be applied toward the purchase price pursuant to the
              terms
              of this LOI. 

          

    

    	11.  	
            On
              or before May 26, 2006, Danzig will cause to be deposited US$325,000
              with
              Davis & Associates in its attorney’s trust account, which will
              represent the balance of the purchase price for the Shares and which
              will
              be held in trust until the earlier of (a)closing, or (b) the termination
              of this LOI.

          

    

    	12.  	
            The
              Closing date for all transactions will be June 26, 2006, unless extended
              in writing and agreed upon by the
              parties.

          

    

    	13.  	
            This
              LOI will terminate immediately and be of no further force or effect
              if
              Danzig or its Buyer is not satisfied with the results of its due
              diligence, and all monies on deposit shall be returned to the entity
              which
              put the funds on deposit.

          

    

    	14.  	
            During
              the 30 days between this date and the closing, you will provide to
              Danzig
              and attorneys for its Buyer to whom it may resell certain of the shares
              received, a copy of all corporate books, records and documents for
              review,
              as part of Danzig’s and Buyer’s due diligence. This will specifically
              include, but not by way of limitation, the Articles, Bylaws and the
              original Minute Books and a current shareholder list for the
              Company.

          

    

    	15.  	
            You
              will instruct the Company’s outside CPA’s and attorneys to interface with
              Danzig and its Buyer, and their advisers, to provide all information
              about
              the Company and answer all questions to the best of their
              knowledge.

          

    

    	16.  	
            Danzig’s
              Buyer will conduct a diligence review of the Company, and may contact
              directly, or through Agents, the Company’s officers, directors, attorneys,
              outside CPA’s, existing creditors, and potential creditors, in connection
              with this review.

          

    

    	17.  	
            The
              Company will have no liabilities at
              closing.

          

    

    	18.  	
            Danzig
              and Danzig’s Buyer must each approve the condition of the Company, as a
              condition precedent to Buyer’s obligations to go forward and close the
              transaction. If Danzig or Danzig’s Buyer or The 124 Group, Inc.
              disapproves the condition of the Company, this LOI shall automatically
              terminate and be of no further force or
              effect.

          

    

    	19.  	
            Prior
              to closing, attorneys for Danzig’s Buyer will prepare a detailed
              representation Agreement, which shall contain the representations and
              warranties Pierce will be required to make as an officer on behalf
              of the
              Company, and as the Seller of the shares, which representations are
              to be
              to the best of his knowledge.

          

    

    	20.  	
            All
              press releases and public announcements regarding the transaction
              contemplated by this LOI will be agreed to and prepared jointly by
              GFR and
              Danzig, unless GFR is required by law to disseminate a news release,
              in
              which case GFR will use its best efforts to implement any comments
              from
              Danzig.

          

    

    	21.  	
            We
              shall each bear our own costs associated with the transaction contemplated
              by this LOI. 

          

    

    	22.  	
            During
              the period of due diligence review, Pierce agrees not to offer the
              shares
              for sale to anyone else, nor to provide any information to any other
              potential buyer for his shares in the
              Company.

          

    

    	23.  	
            The
              operating company that will be merged into the Company after the close,
              (or acquired in a stock for stock exchange), will be Pallane Medical
              Pty,
              Ltd., (or perhaps its US parent). Upon consummation of the acquisition
              of
              Pallane Medical, there will be 18,000,000 shares outstanding. If for
              any
              reason another company other then Pallane Medical, or its US parent,
              is
              proposed to be acquired by the Company, Pierce shall first approve
              in
              writing such other company after receiving full disclosure about it,
              and
              if he does not do so, this LOI shall be of no further force or
              effect.

          

    

    If
      the
      above terms are acceptable, please sign below, whereby this shall become a
      binding agreement between us.

    

    Very
      truly yours,

    

    Danzig,
      Ltd.

    By:
      __/s/
      Elliot Foxcroft__________________

    

    

    Name:
      Elliot Foxcroft

    

    

    Agreed
      and Accepted as of the dated written herein:

    

    

    Richard
      Pierce, Individually: ______/s/
      Richard Pierce_________

    Date:
      

    

    GFR
      PHARMACEUTICALS , Inc. 

    

    By:
      Richard Pierce ______/s/
      Richard Pierce_________

    Title: Chairman
      & CEO

    Date:EX 10.2

     

    MANAGEMENT
      AGREEMENT

     

    This
      management agreement
      dated
      for reference 19 April 2006 is between De
      Beira Goldfields Inc.,
      a
      Nevada corporation (“De
      Beira”)
      with
      an office at 1530 Duthie Avenue, Burnaby, British Columbia, V5A 2R6, and
Reginald
      Gillard,
      of 4
      Mere View Way, Subiaco, Western Australia, 6008.

     

    Whereas
      De Beira
      wishes to appoint Mr. Gillard as president and chief executive officer of De
      Beira , and
      whereas
      Mr.
      Gillard has consented to the appointment of president and chief executive
      officer, for
      valuable consideration,
      the
      receipt and sufficiency of which are acknowledged, and the following mutual
      promises, the parties agree that:

     

    

     

    	1.  	
            Appointment.
              De
              Beira appoints Mr. Gillard as of 19 April 2006 to provide his services
              as
              the president and chief executive officer of De Beira and his business
              management expertise to De Beira in connection with its business
              activities. 

          

     

    	2.  	
            Compensation.
              De
              Beira will pay Mr. Gillard $5,000 Australian dollars per month for
              the
              term of this agreement.

          

     

    	3.  	
            Expenses.
              De
              Beira will reimburse Mr. Gillard for any reasonable out-of-pocket expenses
              that he incurs in fulfilling the terms of this
              agreement.

          

     

    	4.  	
            Term.
              The term of this agreement will be 12 months and this agreement will
              expire on April 18, 2007.

          

     

    	5.  	
            Confidentiality. 

          

     

    	a.  	
            Mr.
              Gillard will hold in the strictest confidence any information about
              De
              Beira or any other affiliated entity that he acquires in the performance
              of his duties under this agreement or otherwise, unless De Beira or
              an
              affiliate has publicly disclosed the information or authorized Mr.
              Gillard
              to disclose it in writing, and will use his best efforts and precautions
              to prevent the unauthorized disclosure of confidential information.
              This
              confidentiality provision survives the termination of this agreement
              and
              Mr. Gillard’s office as president and chief executive
              officer.

          

     

    	b.  	
            Mr.
              Gillard acknowledges the importance and value of confidential information,
              that the unauthorized disclosure of any confidential information could
              cause irreparable harm to De Beira or its affiliates, and that monetary
              damages are an inadequate compensation for Mr. Gillard’s breach of this
              agreement. Accordingly, De Beira and its affiliates may, in addition
              to
              and not in limitation of any other rights, remedies or damages available
              to it in law or equity, obtain a temporary restraining order, a
              preliminary injunction or a permanent injunction in order to prevent
              Mr.
              Gillard from breaching or threatening to breach this
              agreement.

          

     

    	6.  	
            Representations
              and warranties.
              Mr. Gillard represents and warrants that he has the management skills
              and
              experience required to fulfil the duties of president and chief executive
              officer of De Beira and to advise De Beira on its business
              activities.

          

     

    	7.  	
            Termination.
              Either party may terminate this agreement any time for any reason by
              delivering a written notice of termination to the other party 30 days
              before the termination date. De Beira will only be liable to pay Mr.
              Gillard for the 30 days. 

          

     

    	8.  	
            No
              waiver.
              No
              failure or delay of De Beira in exercising any right under this agreement
              operates as a waiver of the right. De Beira’s rights under this agreement
              are cumulative and do not preclude De Beira from relying on or enforcing
              any other legal or equitable right or
              remedy.

          

     

    	9.  	
            Time.
              Time is of the essence.

          

     

    	10.  	
            Jurisdiction.
              This agreement is governed by the laws of the State of
              Nevada.

          

     

    	11.  	
            Severability.
              If
              any part of this agreement that is held to be void or otherwise
              unenforceable by a court or proper legal authority, then that part
              is
              deemed to be amended or deleted from this agreement, and the remainder
              of
              this agreement is valid or otherwise
              enforceable.

          

     

    	12.  	
            Notice.
              Any notice required by or in connection with this agreement be in writing
              and must be delivered to the parties by hand or transmitted by fax
              to the
              address and fax number given for the parties in the recitals. Notice
              is
              deemed to have been delivered when it is delivered by hand or transmitted
              by fax.

          

     

    	13.  	
            Counterparts.
              This agreement may be signed in counterparts and delivered to the parties
              by fax, and the counterparts together are deemed to be one original
              document.

          

     

    The
      parties’ signatures
      below
      are evidence of their agreement.

     

    

    De
      Beira Goldfields Inc.

    

    

    

    /s/
      Michele Fronzo

    

    

    Authorized
      Signatory

    

    

    

    

    

    /s/
      Reginald Gillard

    

    

     Reginald
      Gillard

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]